243 related articles for article (PubMed ID: 18085428)
21. Is haemophilia prophylaxis achievable in the context of self-sufficiency?
Nilsson IM
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S71-5. PubMed ID: 7795143
[TBL] [Abstract][Full Text] [Related]
22. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
Ullman M; Hoots WK
Haemophilia; 2006 Dec; 12 Suppl 6():74-9; discussion 79-80. PubMed ID: 17123398
[TBL] [Abstract][Full Text] [Related]
23. Haemophilia treatment in the United Kingdom from 1969 to 1974.
Biggs R
Br J Haematol; 1977 Apr; 35(4):487-504. PubMed ID: 871406
[TBL] [Abstract][Full Text] [Related]
24. The orthopaedic status of severe haemophiliacs in Spain.
Aznar JA; Magallón M; Querol F; Gorina E; Tusell JM
Haemophilia; 2000 May; 6(3):170-6. PubMed ID: 10792475
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
26. Financing the rising cost of haemophilia care at a large comprehensive care centre.
Miners AH; Sabin CA; Stevens AJ; Tolley KH; Lee CA
J R Coll Physicians Lond; 1997; 31(6):640-4. PubMed ID: 9409497
[TBL] [Abstract][Full Text] [Related]
27. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
28. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group.
Gringeri A; Mantovani LG; Scalone L; Mannucci PM;
Blood; 2003 Oct; 102(7):2358-63. PubMed ID: 12816859
[TBL] [Abstract][Full Text] [Related]
29. Healthcare resource utilization among haemophilia A patients in the United States.
Valentino LA; Pipe SW; Tarantino MD; Ye X; Xiong Y; Luo MP
Haemophilia; 2012 May; 18(3):332-8. PubMed ID: 22044662
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of haemophilia treatment: a cross-national assessment.
Lippert B; Berger K; Berntorp E; Giangrande P; van den Berg M; Schramm W; Siebert U;
Blood Coagul Fibrinolysis; 2005 Oct; 16(7):477-85. PubMed ID: 16175006
[TBL] [Abstract][Full Text] [Related]
31. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
[TBL] [Abstract][Full Text] [Related]
32. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
[TBL] [Abstract][Full Text] [Related]
33. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
Roosendaal G; Lafeber FP
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
[TBL] [Abstract][Full Text] [Related]
34. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome.
Steen Carlsson K; Höjgård S; Glomstein A; Lethagen S; Schulman S; Tengborn L; Lindgren A; Berntorp E; Lindgren B
Haemophilia; 2003 Sep; 9(5):555-66. PubMed ID: 14511294
[TBL] [Abstract][Full Text] [Related]
35. Cost related to replacement therapy during hospitalization in haemophiliacs with or without inhibitors: experience of six French haemophilia centres.
Gautier P; D'Alche-Gautier MJ; Coatmelec B; Marques-Verdier A; Bertrand MA; Dieval J; Berthier AM
Haemophilia; 2002 Sep; 8(5):674-9. PubMed ID: 12199678
[TBL] [Abstract][Full Text] [Related]
36. Haemophilia care in Europe: the ESCHQoL study.
Schramm W; Gringeri A; Ljung R; Berger K; Crispin A; Bullinger M; Giangrande PL; Von Mackensen S; Mantovani LG; Nemes L; Serban M;
Haemophilia; 2012 Sep; 18(5):729-37. PubMed ID: 22639833
[TBL] [Abstract][Full Text] [Related]
37. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
Tortella BJ; Alvir J; McDonald M; Spurden D; Fogarty PF; Chhabra A; Pleil AM
J Manag Care Spec Pharm; 2018 Jul; 24(7):643-653. PubMed ID: 29363389
[TBL] [Abstract][Full Text] [Related]
38. Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries.
O'Mahony B; Noone D; Prihodova L
Haemophilia; 2015 Jul; 21(4):436-43. PubMed ID: 25996253
[TBL] [Abstract][Full Text] [Related]
39. Hemophilia. Treatment of patients with inhibitors: cost issues.
Goudemand J
Haemophilia; 1999 Nov; 5(6):397-401. PubMed ID: 10583526
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome.
Fischer K; van der Bom JG; Molho P; Negrier C; Mauser-Bunschoten EP; Roosendaal G; De Kleijn P; Grobbee DE; van den Berg HM
Haemophilia; 2002 Nov; 8(6):745-52. PubMed ID: 12410642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
